keyword
MENU ▼
Read by QxMD icon Read
search

dementia pet

keyword
https://www.readbyqxmd.com/read/28445082/the-impact-of-%C3%AE-amyloid-positron-emission-tomography-on-the-diagnostic-and-treatment-decisions-of-dementia-experts
#1
Michael L Ganz, Alie F Tawah, Shien Guo, Abhishek S Chitnis, Hedwig Silies, Barbara Schäuble, Aleksandar Jovalekic, Norman L Foster
AIM: Amyloid positron emission tomography (aPET) measurement of Alzheimer's disease (AD) pathology could improve the accurate diagnosis of cognitive disorders. Appropriate use criteria recommend that only dementia experts order aPET. MATERIALS & METHODS: We surveyed 145 dementia experts about their current approaches to evaluation and treatment and the likely influence of aPET. RESULTS: Experts expected aPET to alter diagnostic procedures and patient management and also increase diagnostic certainty...
April 26, 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28441967/comparison-of-csf-markers-and-semi-quantitative-amyloid-pet-in-alzheimer-s-disease-diagnosis-and-in-cognitive-impairment-prognosis-using-the-adni-2-database
#2
Fayçal Ben Bouallègue, Denis Mariano-Goulart, Pierre Payoux
BACKGROUND: The relative performance of semi-quantitative amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) markers in diagnosing Alzheimer's disease (AD) and predicting the cognitive evolution of patients with mild cognitive impairment (MCI) is still debated. METHODS: Subjects from the Alzheimer's Disease Neuroimaging Initiative 2 with complete baseline cognitive assessment (Mini Mental State Examination, Clinical Dementia Rating [CDR] and Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-cog] scores), CSF collection (amyloid-β1-42 [Aβ], tau and phosphorylated tau) and (18)F-florbetapir scans were included in our cross-sectional cohort...
April 26, 2017: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/28434708/dual-phase-18-f-florbetapir-positron-emission-tomography-in-patients-with-primary-progressive-aphasia-alzheimer-s-disease-and-healthy-controls-a-preliminary-study
#3
Hung-Chou Kuo, Ing-Tsung Hsiao, Chia-Ju Hsieh, Chu-Yun Huang, Kuo-Lun Huang, Yau-Yau Wai, Wen-Li Chuang, Mei-Ping Kung, Yi-Chuan Chu, Tzu-Chen Yen, Kun-Ju Lin, Chin-Chang Huang
BACKGROUND: To determine whether dual-phase (18)F-florbetapir positron emission tomography imaging with perfusion-like and amyloid deposition information can distinguish among primary progressive aphasia (PPA), Alzheimer's disease (AD), and healthy controls (HCs). METHODS: Patients diagnosed with PPA, including four semantic dementia (SD) and two progressive nonfluent aphasia (PNFA), as well as one logopenic variant (LV) of PPA, were studied. All PPA patients, and age-/sex-matched patients with probable AD (n=8) and HCs (n=8) were subjected to dual-phase (18)F-florbetapir imaging...
April 20, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28428473/technical-considerations-on-scanning-and-image-analysis-for-amyloid-pet-in-dementia
#4
Go Akamatsu, Akihito Ohnishi, Kazuki Aita, Yasuhiko Ikari, Yasuji Yamamoto, Michio Senda
Brain imaging techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), and positron emission tomography (PET), can provide essential and objective information for the early and differential diagnosis of dementia. Amyloid PET is especially useful to evaluate the amyloid-β pathological process as a biomarker of Alzheimer's disease. This article reviews critical points about technical considerations on the scanning and image analysis methods for amyloid PET...
2017: Nihon Hoshasen Gijutsu Gakkai Zasshi
https://www.readbyqxmd.com/read/28420323/study-protocol-insight-46-a-neuroscience-sub-study-of-the-mrc-national-survey-of-health-and-development
#5
Christopher A Lane, Thomas D Parker, Dave M Cash, Kirsty Macpherson, Elizabeth Donnachie, Heidi Murray-Smith, Anna Barnes, Suzie Barker, Daniel G Beasley, Jose Bras, David Brown, Ninon Burgos, Michelle Byford, M Jorge Cardoso, Ana Carvalho, Jessica Collins, Enrico De Vita, John C Dickson, Norah Epie, Miklos Espak, Susie M D Henley, Chandrashekar Hoskote, Michael Hutel, Jana Klimova, Ian B Malone, Pawel Markiewicz, Andrew Melbourne, Marc Modat, Anette Schrag, Sachit Shah, Nikhil Sharma, Carole H Sudre, David L Thomas, Andrew Wong, Hui Zhang, John Hardy, Henrik Zetterberg, Sebastien Ourselin, Sebastian J Crutch, Diana Kuh, Marcus Richards, Nick C Fox, Jonathan M Schott
BACKGROUND: Increasing age is the biggest risk factor for dementia, of which Alzheimer's disease is the commonest cause. The pathological changes underpinning Alzheimer's disease are thought to develop at least a decade prior to the onset of symptoms. Molecular positron emission tomography and multi-modal magnetic resonance imaging allow key pathological processes underpinning cognitive impairment - including β-amyloid depostion, vascular disease, network breakdown and atrophy - to be assessed repeatedly and non-invasively...
April 18, 2017: BMC Neurology
https://www.readbyqxmd.com/read/28410658/the-role-of-neuroimaging-in-the-assessment-of-the-cognitively-impaired-elderly
#6
REVIEW
Sara Kollack-Walker, Collin Y Liu, Adam S Fleisher
This article reviews the current diagnostic tools that are available for structural, functional, and molecular imaging of the brain, summarizing some of the key findings that have been reported in individuals diagnosed with Alzheimer disease, mild cognitive impairment, prodromal AD, or other prevalent dementias. Given recent advances in the development of amyloid PET tracers, current guidelines for the use of amyloid PET imaging in patients with cognitive complaints are reviewed. In addition, data addressing the potential value of amyloid PET imaging in the clinical setting are highlighted...
May 2017: Neurologic Clinics
https://www.readbyqxmd.com/read/28399252/association-between-midlife-vascular-risk-factors-and-estimated-brain-amyloid-deposition
#7
Rebecca F Gottesman, Andrea L C Schneider, Yun Zhou, Josef Coresh, Edward Green, Naresh Gupta, David S Knopman, Akiva Mintz, Arman Rahmim, A Richey Sharrett, Lynne E Wagenknecht, Dean F Wong, Thomas H Mosley
Importance: Midlife vascular risk factors have been associated with late-life dementia. Whether these risk factors directly contribute to brain amyloid deposition is less well understood. Objective: To determine if midlife vascular risk factors are associated with late-life brain amyloid deposition, measured using florbetapir positron emission tomography (PET). Design, Setting, and Participants: The Atherosclerosis Risk in Communities (ARIC)-PET Amyloid Imaging Study, a prospective cohort study among 346 participants without dementia in 3 US communities (Washington County, Maryland; Forsyth County, North Carolina; and Jackson, Mississippi) who have been evaluated for vascular risk factors and markers since 1987-1989 with florbetapir PET scans in 2011-2013...
April 11, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28394771/tau-pet-binding-distinguishes-patients-with-early-stage-posterior-cortical-atrophy-from-amnestic-alzheimer-disease-dementia
#8
Gregory S Day, Brian A Gordon, Kelley Jackson, Jon J Christensen, Maria Rosana Ponisio, Yi Su, Beau M Ances, Tammie L S Benzinger, John C Morris
BACKGROUND: Flortaucipir (tau) positron emission tomography (PET) binding distinguishes individuals with clinically well-established posterior cortical atrophy (PCA) due to Alzheimer disease (AD) from cognitively normal (CN) controls. However, it is not known whether tau-PET binding patterns differentiate individuals with PCA from those with amnestic AD, particularly early in the symptomatic stages of disease. METHODS: Flortaucipir and florbetapir (β-amyloid) PET imaging were performed in individuals with early-stage PCA (N=5), amnestic AD dementia (N=22), and CN controls (N=47)...
April 7, 2017: Alzheimer Disease and Associated Disorders
https://www.readbyqxmd.com/read/28390530/neurologic-applications-of-pet-mr-imaging
#9
REVIEW
Michelle M Miller-Thomas, Tammie L S Benzinger
PET/MR imaging benefits neurologic clinical care and research by providing spatially and temporally matched anatomic MR imaging, advanced MR physiologic imaging, and metabolic PET imaging. MR imaging sequences and PET tracers can be modified to target physiology specific to a neurologic disease process, with applications in neurooncology, epilepsy, dementia, cerebrovascular disease, and psychiatric and neurologic research. Simultaneous PET/MR imaging provides efficient acquisition of multiple temporally matched datasets, and opportunities for motion correction and improved anatomic assignment of PET data...
May 2017: Magnetic Resonance Imaging Clinics of North America
https://www.readbyqxmd.com/read/28387722/translocator-protein-18-kda-tspo-positron-emission-tomography-pet-imaging-and-its-clinical-impact-in-neurodegenerative-diseases
#10
REVIEW
Anne-Claire Dupont, Bérenger Largeau, Maria Joao Santiago Ribeiro, Denis Guilloteau, Claire Tronel, Nicolas Arlicot
In vivo exploration of activated microglia in neurodegenerative diseases is achievable by Positron Emission Tomography (PET) imaging, using dedicated radiopharmaceuticals targeting the translocator protein-18 kDa (TSPO). In this review, we emphasized the major advances made over the last 20 years, thanks to TSPO PET imaging, to define the pathophysiological implication of microglia activation and neuroinflammation in neurodegenerative diseases, including Parkinson's disease, Huntington's disease, dementia, amyotrophic lateral sclerosis, multiple sclerosis, and also in psychiatric disorders...
April 7, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28385579/memory-self-awareness-in-the-preclinical-and-prodromal-stages-of-alzheimer-s-disease
#11
Patrizia Vannini, Rebecca Amariglio, Bernard Hanseeuw, Keith A Johnson, Donald G McLaren, Jasmeer Chhatwal, Alvaro Pascual-Leone, Dorene Rentz, Reisa A Sperling
While loss of insight of cognitive deficits, anosognosia, is a common symptom in Alzheimer's disease dementia, there is a lack of consensus regarding the presence of altered awareness of memory function in the preclinical and prodromal stages of the disease. Paradoxically, very early in the Alzheimer's disease process, individuals may experience heightened awareness of memory changes before any objective cognitive deficits can be detected, here referred to as hypernosognosia. In contrast, awareness of memory dysfunction shown by individuals with mild cognitive impairment (MCI) is very variable, ranging from marked concern to severe lack of insight...
May 2017: Neuropsychologia
https://www.readbyqxmd.com/read/28385551/down-syndrome-age-dependence-of-pib-binding-in-postmortem-frontal-cortex-across-the-lifespan
#12
Harry LeVine, H Peter Spielmann, Sergey Matveev, Francesca Macchiavello Cauvi, M Paul Murphy, Tina L Beckett, Katie McCarty, Ira T Lott, Eric Doran, Frederick Schmitt, Elizabeth Head
Beta-amyloid (Aβ) deposition in brain accumulates as a function of age in people with Down syndrome (DS) with subsequent development into Alzheimer disease neuropathology, typically by 40 years of age. In vivo imaging using the Pittsburgh compound B (PiB) ligand has facilitated studies linking Aβ, cognition, and dementia in DS. However, there are no studies of PiB binding across the lifespan in DS. The current study describes in vitro (3)H-PiB binding in the frontal cortex of autopsy cases with DS compared to non-DS controls...
June 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28383676/biochemically-defined-pools-of-amyloid-%C3%AE-in-sporadic-alzheimer-s-disease-correlation-with-amyloid-pet
#13
Blaine R Roberts, Monica Lind, Aaron Z Wagen, Alan Rembach, Tony Frugier, Qiao-Xin Li, Timothy M Ryan, Catriona A McLean, James D Doecke, Christopher C Rowe, Victor L Villemagne, Colin L Masters
We fractionated frontal cortical grey matter from human Alzheimer's disease and control subjects into four biochemically defined pools that represent four distinct compartments: soluble/cytosolic, peripheral membrane/vesicular cargo, integral lipid/membranous pools and aggregated/insoluble debris. Most of the readily extractable amyloid-β remains associated with a lipid/membranous compartment. There is an exchange of amyloid-β between the biochemical pools that was lost for the amyloid-β42 species in Alzheimer's disease, consistent with the peptide being irreversibly trapped in extracellular deposits...
March 5, 2017: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/28376695/added-value-and-limitations-of-amyloid-pet-imaging-review-and-analysis-of-selected-cases-of-mild-cognitive-impairment-and-dementia
#14
David A Weidman, Edward Zamrini, Marwan N Sabbagh, Sandra Jacobson, Anna Burke, Christine Belden, Jessica Powell, Nidhi Bhalla, Auttawut Roontiva, Xiaoying Kuang, Ji Luo, Kewei Chen, Garrett Riggs, William Burke
Amyloid-positron emission tomography (PET) imaging of the brain detects elevated amyloid-beta (amyloid-β) neuritic plaques in vivo, which can be helpful in appropriately selected cases of mild cognitive impairment (MCI) and dementia, when Alzheimer's disease remains a possible etiology, after a comprehensive clinical evaluation. We reviewed cases of cognitively impaired patients who underwent amyloid-PET imaging because of diagnostic uncertainty. Pre- and post-PET elements of diagnosis and management were first compared, to assess impact of scan results on clinical decision-making, and then an analysis of those decisions was undertaken in appropriate clinical situations, to delineate the added value and limitations of amyloid-PET imaging...
February 2017: Neurocase
https://www.readbyqxmd.com/read/28374078/arterial-spin-labeling-based-z-maps-have-high-specificity-and-positive-predictive-value-for-neurodegenerative-dementia-compared-to-fdg-pet
#15
David Fällmar, Sven Haller, Johan Lilja, Torsten Danfors, Lena Kilander, Nelleke Tolboom, Karl Egger, Elias Kellner, Philip M Croon, Sander C J Verfaillie, Bart N M van Berckel, Rik Ossenkoppele, Frederik Barkhof, Elna-Marie Larsson
OBJECTIVE: Cerebral perfusion analysis based on arterial spin labeling (ASL) MRI has been proposed as an alternative to FDG-PET in patients with neurodegenerative disease. Z-maps show normal distribution values relating an image to a database of controls. They are routinely used for FDG-PET to demonstrate disease-specific patterns of hypometabolism at the individual level. This study aimed to compare the performance of Z-maps based on ASL to FDG-PET. METHODS: Data were combined from two separate sites, each cohort consisting of patients with Alzheimer's disease (n = 18 + 7), frontotemporal dementia (n = 12 + 8) and controls (n = 9 + 29)...
April 3, 2017: European Radiology
https://www.readbyqxmd.com/read/28365320/use-of-white-matter-reference-regions-for-detection-of-change-in-florbetapir-positron-emission-tomography-from-completed-phase-3-solanezumab-trials
#16
Adam S Fleisher, Abhinay D Joshi, Karen L Sundell, Yun-Fei Chen, Sara Kollack-Walker, Ming Lu, Sherry Chen, Michael D Devous, John Seibyl, Kenneth Marek, Eric R Siemers, Mark A Mintun
INTRODUCTION: We compared subject-specific white matter (SSWM) and whole cerebellum (CBL) reference regions for power to detect longitudinal change in amyloid positron emission tomography signal. METHODS: Positive florbetapir positron emission tomography scans were analyzed from participants (66 placebo treated and 63 solanezumab treated) with mild dementia caused by Alzheimer's disease from the EXPEDITION and EXPEDITION2 studies. For comparison to CBL, a second normalization was performed on longitudinal data using an SSWM correction factor (SSWM normalization ratio [SSWMnr])...
March 30, 2017: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/28346578/association-of-plasma-neurofilament-light-with-neurodegeneration-in-patients-with-alzheimer-disease
#17
Niklas Mattsson, Ulf Andreasson, Henrik Zetterberg, Kaj Blennow
Importance: Existing cerebrospinal fluid (CSF) or imaging (tau positron emission tomography) biomarkers for Alzheimer disease (AD) are invasive or expensive. Biomarkers based on standard blood test results would be useful in research, drug development, and clinical practice. Plasma neurofilament light (NFL) has recently been proposed as a blood-based biomarker for neurodegeneration in dementias. Objective: To test whether plasma NFL concentrations are increased in AD and associated with cognitive decline, other AD biomarkers, and imaging evidence of neurodegeneration...
March 27, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/28336779/validation-of-the-semi-quantitative-static-suvr-method-for-18-f-av45-pet-by-pharmacokinetic-modeling-with-an-arterial-input-function
#18
Julie Ottoy, Jeroen Verhaeghe, Ellis Niemantsverdriet, Leonie Wyffels, Charisse Somers, Ellen De Roeck, Hanne Struyfs, Femke Soetewey, Steven Deleye, Tobi Van den Bossche, Sara Van Mossevelde, Sarah Ceyssens, Jan Versijpt, Sigrid Stroobants, Sebastiaan Engelborghs, Steven Staelens
Increased brain uptake of [(18)F]-AV45 visualized by PET is a key biomarker for Alzheimer's disease (AD). The standardized uptake value ratio (SUVR) is widely used for quantification, but is subject to variability based on choice of reference region and changes in cerebral blood flow. Here we validate the SUVR method against the gold standard volume of distribution (VT) to assess cross-sectional differences in plaque load. Methods: Dynamic 60-min [(18)F]-AV45 (291 ± 67 MBq) and 1-min [(15)O]-H2O (370 MBq) scans were obtained in 35 age-matched elderly subjects, including 10 probable AD dementia, 15 amnestic mild cognitive impairment (aMCI) and 10 cognitively healthy controls (HC)...
March 23, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28334939/association-between-tau-deposition-and-antecedent-amyloid-%C3%AE-accumulation-rates-in-normal-and-early-symptomatic-individuals
#19
Duygu Tosun, Susan Landau, Paul S Aisen, Ronald C Petersen, Mark Mintun, William Jagust, Michael W Weiner
A long-term goal of our field is to determine the sequence of pathological events, which ultimately lead to cognitive decline and dementia. In this study, we first assessed the patterns of brain tau tangle accumulation (measured with the positron emission tomography tracer 18F-AV-1451) associated with well-established Alzheimer's disease factors in a cohort including cognitively healthy elderly individuals and individuals at early symptomatic stages of Alzheimer's disease. We then explored highly associated patterns of greater 18F-AV-1451 binding and increased annualized change in cortical amyloid-β plaques measured as florbetapir positron emission tomography binding antecedent to 18F-AV-1451 positron emission tomography scans, and to what extent these multimodal pattern associations explained the variance in cognitive performance and clinical outcome measures, independently and jointly...
March 17, 2017: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/28331953/value-of-fdg-pet-scans-of-non-demented-patients-in-predicting-rates-of-future-cognitive-and-functional-decline
#20
Nare Torosyan, Kelsey Mason, Magnus Dahlbom, Daniel H S Silverman
PURPOSE: The aim of this study was to examine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting subsequent rates of functional and cognitive decline among subjects considered cognitively normal (CN) or clinically diagnosed with mild cognitive impairment (MCI). METHODS: Analyses of 276 subjects, 92 CN subjects and 184 with MCI, who were enrolled in the Alzheimer's Disease Neuroimaging Initiative, were conducted. Functional decline was assessed using scores on the Functional Activities Questionnaire (FAQ) obtained over a period of 36 months, while cognitive decline was determined using the Alzheimer's disease Assessment Scale-Cognitive subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE) scores...
March 22, 2017: European Journal of Nuclear Medicine and Molecular Imaging
keyword
keyword
68325
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"